Approximately 10% of colorectal cancers harbor native mutations in PTPRS, and inactivation of PTPRS promotes ERK and AKT activation, resulting in enhanced RAS and EGFR activity in colorectal cancer (Davis et al., 2018). The gene discussed is PTPRS; the disease is colorectal cancer.